

Teva Pharmaceutical Industries Ltd.

---

# Second Quarter 2017 Results

August 3, 2017

The logo for Teva Pharmaceutical Industries, consisting of the word "TEVA" in a bold, white, sans-serif font, centered within a dark blue square.

# Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

- our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc's worldwide generic pharmaceuticals business ("Actavis Generics"); our ability to realize the anticipated benefits of the acquisition (and any delay in realizing those benefits) or difficulties in integrating Actavis Generics; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our generic products, both from competing products and as a result of increased governmental pricing pressures; and our ability to take advantage of high-value biosimilar opportunities;
- our specialty medicines business, including: competition for our specialty products, especially Copaxone®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a downgrade of our credit ratings;
- our business and operations in general, including: uncertainties relating to our recent senior management changes; our ability to develop and commercialize additional pharmaceutical products; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain, including due to labor unrest; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel, including those who joined us as part of the Actavis Generics acquisition; the restructuring of our manufacturing network, including potential related labor unrest, including a potential workers' strike; the impact of continuing consolidation of our distributors and customers; variations in patent laws that may adversely affect our ability to manufacture our products; our ability to consummate dispositions on terms acceptable to us; adverse effects of political or economic instability, major hostilities or terrorism on our significant worldwide operations; and our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions;
- compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; governmental investigations into sales and marketing practices; potential liability for sales of generic products prior to a final resolution of outstanding patent litigation; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; the significant increase in our intangible assets, which may result in additional substantial impairment charges; potentially significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 ("Annual Report"), including in the section captioned "Risk Factors," and in our other filings with the U.S. Securities and Exchange Commission, which are available at [www.sec.gov](http://www.sec.gov) and [www.tevapharm.com](http://www.tevapharm.com). Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

## Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures as defined by SEC rules. Please see our Annual Report on Form 20-F for the year ended December 31, 2016 for a reconciliation of those historical measures to the most directly comparable GAAP measures. The estimates contained in this presentation are non-GAAP financial measures, which exclude the amortization of purchased intangible assets, costs related to certain regulatory actions, inventory step-up, legal settlements and reserves, impairments and other costs and related tax effects. The non-GAAP data presented by Teva are the results used by Teva's management and board of directors to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management. Teva provides such non-GAAP data to investors as supplemental data and not in substitution or replacement for GAAP measure, because management believes such data provides useful information to investors. A reconciliation of such forward-looking non-GAAP estimates to the corresponding GAAP measures is not being provided, due to the unreasonable efforts required to prepare it.

Dr. Yitzhak Peterburg  
Interim President & CEO

Mike McClellan  
Interim Chief Financial Officer

# Q2 2017 Results

## Q2 2017 P&L Highlights

\$ millions, except EPS	Q2 2017	Q2 2016	Q2 2017	Q2 2016
	GAAP		Non-GAAP	
Revenues	5,686	5,038	5,686	5,038
Operating income (loss)	(5,740) (100.9%)	361 7.2%	1,597 28.1%	1,583 31.4%
Net income (loss) attributable to Teva	(5,970)	254	1,100	1,228
EPS (\$)	(5.94) 1,017M shares	0.20 920M shares	1.02 1,017M shares	1.25 979M shares

## Q2 2017 Non-GAAP P&L Highlights

\$ billions, except EPS	Q2 2017	Q2 2016	Change
Revenues	5.7	5.0	+13%
Operating income	1.6 28.1%	1.6 31.4%	+1%
EBITDA	1.7	1.7	+3%
Net income	1.1	1.2	(10%)
EPS (\$)	1.02 1,017M shares	1.25 979M shares	(18%)
Cash flow from operations	0.7	1.0	(23%)
Free cash flow	0.6	0.8	(29%)

Operating income, EBITDA, net income and EPS are presented on a non-GAAP basis.

## Q2 2017 Non-GAAP Adjustments

\$ millions	Q2 2017	Details
Goodwill impairment	6,100	US generics
Amortization	411	Including Actavis PPA adjustment
Legal settlements	324	Carvedilol patent litigation reserve (\$235m)
Impairment	145	Godollo closure (\$68m), Rimsa (\$43m)
Contingent consideration	140	Bendeka® royalties (\$98m)
Restructuring, acquisition and integration expenses	131	
IPR&D	26	Regeneron (\$25m)
Other adjustments	45	
Related tax effect	-252	
<b>Total adjustments</b>	<b>7,070</b>	



## Balance Sheet

\$ billions	Jun 30, 2017	Mar 31, 2017	Diff
Cash and Cash Equivalents	0.6	0.9	-0.3
Other Financial assets	0.3	0.3	0.0
AR Trade	7.4	7.3	0.1
Pre-paid Expenses and Other Current Assets	1.5	1.7	-0.1
Inventory	5.1	5.0	0.1
Fixed Assets	8.1	8.2	-0.1
Goodwill	40.0	45.0	-5.0
Intangible Assets	21.7	21.2	0.5
Other Long Term Assets	1.7	1.7	0.0
<b>Total Assets</b>	<b>86.4</b>	<b>91.3</b>	<b>-4.9</b>
AP Trade	2.2	2.3	-0.1
SR&A	7.6	7.5	0.1
AP Other	4.4	4.1	0.3
Total Debt (ST+LT)	35.1	34.6	0.4
Other Long Term liabilities	7.5	6.9	0.6
Minority	1.6	1.7	-0.1
Teva Shareholders' Equity	28.0	34.0	-6.0
<b>Total Liabilities &amp; Equity</b>	<b>86.4</b>	<b>91.3</b>	<b>-4.9</b>


## Q2 2017 Foreign Exchange & Venezuela Impact

\$ millions	Q2 2017	Q2 2016	Diff	FX Effect	Venezuela
Revenues	5,686	5,038	648	(35)	(183)
Operating income (loss) GAAP	(5,740)	361	(6,101)	(15)	(47)
Operating income Non-GAAP	1,597	1,583	14	(18)	(38)

In light of the political and economic conditions in Venezuela, we exclude the changes in revenues and operating profit in the country from any discussion of currency translation effects.

## Quarterly EBITDA

\$ billions



EBITDA is based on non-GAAP operating income (which excludes amortization and certain other items) and excludes depreciation expenses.

# Cash Flow

\$ millions

Cash flow from Operations


963

1,461

1,425

470


741



\* Proceeds from divestitures related to Actavis Generics were \$1.7 billion in Q3 2016 and \$0.7 billion in Q1 2017.

# Liquidity

\$ billions



Leverage

25%

50%

51%

49%

54%

Debt/EBITDA

1.66

5.38

4.87

4.63

4.65

Net Debt/EBITDA

0.58

5.13

4.72


4.49

4.56

EBITDA is based on non-GAAP operating income (which excludes amortization and certain other items) and excludes depreciation expenses.

# Quarterly Revenues


\$ millions



All data, except FX and VZ nominal, are net of the impact of foreign exchange fluctuations.


# Quarterly Revenue Breakdown by Business Line

\$ millions



# Quarterly Non-GAAP Operating Profit


\$ millions



Segment profit consists of gross profit, less S&M and R&D expenses related to the segment, but excludes G&A expenses, amortization, and certain other items.




## Generics Segment Gross Profit and Profit Margin



Segment profit consists of gross profit, less S&M and R&D expenses related to the segment, but excludes G&A expenses, amortization, inventory step-up and certain other items.

# Copaxone<sup>®</sup> revenues and US market shares

\$ millions / % market share



# Financial Outlook

## 2017 non-GAAP P&L outlook

billions, except EPS	2017 Business Outlook January 2017	Updated Business Outlook August 2017
<b>Net revenues</b>	<b>23.8 - 24.5</b>	<b>22.8 - 23.2</b>
Gross profit (%)	57% - 58%	56% - 57%
R&D	1.75 - 1.85	1.6 - 1.7
S&M	3.4 - 3.55	3.45 - 3.55
G&A	1.0 - 1.1	1.1 - 1.2
<b>Operating income (\$B)</b>	<b>7.4 - 7.8</b>	<b>6.6 - 6.8</b>
<b>EBITDA</b>	<b>8.0 - 8.4</b>	<b>7.2 - 7.4</b>
Finance expenses	0.8 - 0.85	0.8 - 0.9
Tax (%)	17% - 18%	16.5% - 17.5%
Number of shares (M)	1,076	1,076*
<b>EPS</b>	<b>4.90 - 5.30</b>	<b>4.30 - 4.50</b>
<b>Cash flow from operations</b>	<b>5.7 - 6.1</b>	<b>4.4 - 4.6</b>

\* If annual EPS is below \$4.37, the mandatory convertible preferred shares will be anti-dilutive and the number of shares will be 1,017 with no impact on guided EPS of \$4.30-\$4.50. See slide 29 for additional information.

Dr. Sol J. Barer  
Chairman of the Board

Q&A

# Additional Information

## Quarterly GAAP P&L

\$ millions, except EPS	Q2-17	Q2-17 Margins	Q2-16	Q2-16 Margins	Diff
Revenues	5,686		5,038		+13%
COGS	2,865	50.4%	2,161	42.9%	+33%
Gross profit	2,821	49.6%	2,877	57.1%	(2%)
R&D	486	8.5%	375	7.4%	+30%
S&M	960	16.9%	952	18.9%	+1%
G&A	272	4.8%	311	6.2%	(13%)
Legal settlements and loss contingencies	324	5.7%	166	3.3%	+95%
Impairments, restructuring and others	6,519	114.7%	712	14.1%	n/a
<b>Operating income (loss)</b>	<b>(5,740)</b>	<b>(100.9%)</b>	<b>361</b>	<b>7.2%</b>	<b>n/a</b>
Finance exp.	238	4.2%	105	2.1%	+127%
Tax	(22)	0.4%	29	11.3%	(176%)
Minority and share in profit	14	0.2%	(27)	(0.5%)	(152%)
<b>Net income (loss) attributable to Teva</b>	<b>(5,970)</b>	<b>(105.0%)</b>	<b>254</b>	<b>5%</b>	<b>n/a</b>
Dividends on preferred shares	65		66		
<b>Net income (loss) attributable to ordinary shareholders</b>	<b>(6,035)</b>		<b>188</b>		
# of shares (diluted, millions)	1,017		920		
<b>EPS (\$)</b>	<b>(5.94)</b>		<b>0.20</b>		<b>n/a</b>



## Quarterly Non-GAAP P&L

\$ millions, except EPS	Q2-17	Q2-17 Margins	Q2-16	Q2-16 Margins	Diff
Revenues	5,686		5,038		+13%
COGS	2,459	43.2%	1,888	37.5%	+30%
Gross profit	3,227	<b>56.8%</b>	3,150	<b>62.5%</b>	+2%
R&D	450	7.9%	370	7.3%	+22%
S&M	906	15.9%	898	17.8%	+1%
G&A	274	4.8%	299	5.9%	(8%)
Operating income	1,597	<b>28.1%</b>	1,583	<b>31.4%</b>	+1%
Finance exp.	235		6		
Tax	230	16.9%	333	21.1%	(31%)
Net income attributable to Teva	1,100	<b>19.3%</b>	1,228	<b>23.1%</b>	<b>(10%)</b>
Dividends on preferred shares	65		66		
Net income attributable to ordinary shareholders	1,035		1,162		
Net income attributable to ordinary shareholders for diluted EPS*	1,035		1,228		
# of shares (diluted, millions)	1,017		979		
EPS (\$)	1.02		1.25		<b>(18%)</b>

\* Dividends on the mandatory convertible preferred shares of \$66 million in Q2 2016 were added back to non-GAAP net income attributable to ordinary shareholders, since such preferred shares had a dilutive effect on non-GAAP earnings per share.

# H1 GAAP P&L

\$ millions, except EPS	H1-17	H1-17 Margins	H1-16	H1-16 Margins	Diff
Revenues	11,316		9,848		+15%
COGS	5,676	50.2%	4,180	42.4%	+36%
Gross profit	5,640	49.8%	5,668	57.6%	+0%
R&D	943	8.3%	764	7.8%	+23%
S&M	1,931	17.1%	1,791	18.2%	+8%
G&A	508	4.5%	615	6.2%	(17%)
Legal settlements and loss contingencies	344	3.0%	141	1.4%	+144%
Impairments, restructuring and others	6,759	59.7%	831	8.4%	n/a
<b>Operating income (loss)</b>	<b>(4,845)</b>	<b>(42.8%)</b>	<b>1,526</b>	<b>15.5%</b>	<b>n/a</b>
Finance exp.	445	3.9%	403	4.1%	+10%
Tax	32	(0.6%)	257	22.9%	(88%)
Minority and share in profit	3	0.0%	(24)	(0.2%)	(113%)
<b>Net income (loss) attributable to Teva</b>	<b>(5,325)</b>	<b>(47.1%)</b>	<b>890</b>	<b>9.0%</b>	<b>n/a</b>
Dividends on preferred shares	130		132		
<b>Net income (loss) attributable to ordinary shareholders</b>	<b>(5,445)</b>		<b>758</b>		
# of shares (diluted, millions)	1,016		922		
<b>EPS (\$)</b>	<b>(5.37)</b>		<b>0.82</b>		<b>n/a</b>

# H1 2017 Non-GAAP Adjustments

\$ millions	H1 2017	Details
Goodwill impairment	6,100	US generics
Amortization	731	
Legal settlements	344	Carvedilol patent litigation reserve (\$235m)
Restructuring, acquisition and integration expenses	284	
Contingent consideration	161	Bendeka <sup>®</sup> royalties (\$98m)
Impairment	156	Godollo closure (\$68m), Rimsa (\$43m)
IPR&D	26	Regeneron (\$25m)
Regulatory actions	49	Godollo (\$36m), Rimsa (\$8m)
Other adjustments	156	
Related tax effect	-438	
<b>Total adjustments</b>	<b>7,569</b>	

# H1 Non-GAAP P&L

\$ millions, except EPS	H1-17	H1-17 Margins	H1-16	H1-16 Margins	Diff
Revenues	11,316		9,848		+15%
COGS	4,893	43.2%	3,682	37.4%	+33%
Gross profit	6,423	56.8%	6,166	62.6%	+4%
R&D	896	7.9%	745	7.6%	+20%
S&M	1,813	16.0%	1,719	17.5%	+5%
G&A	496	4.4%	593	6.0%	(16%)
Operating income	3,218	28.4%	3,109	31.6%	+4%
Finance exp.	470		58		+710%
Tax	470	17.1%	635	20.8%	(26%)
Net income attributable to Teva	2,244	19.8%	2,400	24.4%	(7%)
Dividends on preferred shares	130		132		
Net income attributable to ordinary shareholders	2,114		2,268		
Net income attributable to ordinary shareholders for diluted EPS*	2,114		2,400		
# of shares (diluted, millions)	1,017		981		
EPS (\$)	2.08		2.45		(15%)

\* Dividends on the mandatory convertible preferred shares of \$132 million in H1 2016 were added back to non-GAAP net income attributable to ordinary shareholders, since such preferred shares had a dilutive effect on non-GAAP earnings per share.

## 2017 non-GAAP P&L outlook

billions, except EPS	2017 Business Outlook January 2017	Updated Business Outlook August 2017
Net revenues	23.8-24.5	22.8-23.2
Gross profit (%)	57%-58%	56 %-57%
R&D	1.75-1.85	1.6-1.7
S&M	3.4-3.55	3.45-3.55
G&A	1.0-1.1	1.1-1.2
Operating income (\$B)	7.4-7.8	6.6-6.8
EBITDA	8.0-8.4	7.2-7.4
Finance expenses	0.8-0.85	0.8-0.9
Tax (%)	17%-18%	16.5-17.5%
Net income attributable to ordinary shareholders		4.4-4.6
Number of shares (M)	1,076	1,017
EPS	4.90-5.30	4.30-4.50
Cash flow from operations	5.7-6.1	4.4-4.6